Clinical Trials Directory

Trials / Completed

CompletedNCT03061123

Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular AF

Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular Atrial Fibrillation

Status
Completed
Phase
Study type
Observational
Enrollment
91 (actual)
Sponsor
Medical University of Graz · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The risk of stroke is markedly elevated in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is indicated in individuals with moderate and high risk of stroke to the disadvantage of an increased burden from bleeding. Adequate knowledge of this disorder and understanding the benefits and hazards of antithrombotic treatment are essential to incorporate patient´s values and preferences in these decisions. This will further improve acceptance of recommended therapy and augment compliance with OAC. The objective of this investigation is to compare patient´s perceptions and physician´s assessments of benefits and risks of OAC.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnaire

Timeline

Start date
2015-09-01
Primary completion
2017-10-01
Completion
2017-10-01
First posted
2017-02-23
Last updated
2023-09-15

Locations

8 sites across 1 country: Austria

Source: ClinicalTrials.gov record NCT03061123. Inclusion in this directory is not an endorsement.

Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular AF (NCT03061123) · Clinical Trials Directory